Artiva Biotherapeutics, Inc. is a clinical-stage biotech firm based in San Diego that develops allogeneic, off-the-shelf natural killer cell therapies aimed at autoimmune diseases. Its lead candidate, AlloNK (AB-101), was a non-genetically modified, cryopreserved NK cell therapy intended to boost the antibody-dependent cellular cytotoxicity of anti-CD20 antibodies and achieve deep B-cell depletion. The company had been advancing AlloNK combined with rituximab in indications including rheumatoid arthritis, Sjögren disease, systemic sclerosis, and myositis. ARTV listed on the Nasdaq Global Market in July 2024 and, before the October 2026 update, had been preparing to start a Phase 3 trial in refractory RA.
Over the last 30 days, ARTV declined about 33%, moving from a closing price near $5.91 in mid-October to roughly $3.95. Most of the move occurred on October 27, 2026, when the stock fell 30.68% to close at $4.27 after the company disclosed it would halt AlloNK development. Shares continued to ease lower in the following weeks as the clinical program wound down and the strategic review progressed. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The three-month view shows an even steeper decline. In mid-August, ARTV traded around $11.30 on the back of early Phase 2a data and raised analyst targets. Over the next three months the stock lost roughly 65% of its value as clinical setbacks mounted and ultimately led to the discontinuation of the sole lead program.
The key event was the October 27, 2026 announcement that Artiva would discontinue further work on AlloNK. While updated data still showed deep B-cell depletion and clinical activity in line with earlier results, longer-term follow-up fell short of the durability needed to justify continued development. The decision was also influenced by two Grade 5 safety events: one case of leukoencephalopathy likely linked to fludarabine-associated neurotoxicity and a second sudden-death event deemed unrelated to treatment.
Along with the halt, Artiva disclosed a roughly 94% workforce reduction and stated it is evaluating strategic alternatives to maximize stockholder value, which could include a merger, business combination, asset sale or licensing, or dissolution and liquidation. The company retained Leerink Partners as financial advisor and reported approximately $319.1 million in cash, cash equivalents, and investments as of September 30, 2026. The single-day 30.68% drop reflected the market’s reassessment once the lead asset was removed.
The broader three-month decline marks a sharp reversal. As recently as August 2026, Artiva had reported encouraging early data in difficult-to-treat RA patients, received FDA RMAT designation for AlloNK plus rituximab in refractory RA, and completed an approximately $300 million offering in May 2026 to support Phase 3 plans. Sell-side analysts had raised price targets on the strength of those results.
Optimism faded through September and October as safety concerns surfaced and the FDA requested a pause in enrollment and dosing in the Phase 2a basket trial. The downward move accelerated into the late-October decision to stop development entirely, removing much of the value previously attached to AlloNK’s clinical and commercial potential.
Going forward, the main variable remains the outcome of the strategic-alternatives process. Investors will track whether the board pursues a merger, business combination, asset sale or licensing deal, or instead moves toward dissolution and liquidation. The company’s final cash position and wind-down costs—estimated at roughly $10 million to $15 million for contract terminations and $17 million to $20 million in severance-related expenses—will also draw attention.
Other items include any resolution of litigation or regulatory inquiries, such as the shareholder investigation announced in November 2026, plus updates on remaining assets. Because Artiva has indicated it does not plan to provide further updates unless the board approves a specific path, periods of limited disclosure could continue. These factors carry substantial uncertainty, and no particular outcome is assured.
When reviewing fast-moving biotech names like this, I often consult Tickeron’s AI Trading Bots to compare automated strategies across similar tickers and timeframes. The platform lets users filter bots by performance metrics and risk parameters, which helps place individual stock moves in a broader, data-driven context without replacing fundamental analysis.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 13 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for ARTV just turned positive on November 09, 2026. Looking at past instances where ARTV's MACD turned positive, the stock continued to rise in 20 of 21 cases over the following month. The odds of a continued upward trend are 90%.
Following a +2.18% 3-day Advance, the price is estimated to grow further. Considering data from situations where ARTV advanced for three days, in 95 of 110 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
ARTV may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARTV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for ARTV entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 49 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.584) is normal, around the industry mean (3.498). P/E Ratio (-1.285) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.658) among similar stocks. P/S Ratio (81.301) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating steady price growth. ARTV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARTV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry Biotechnology